PremiumThe FlyAcrivon Therapeutics to presents data on deployment of AP3 platform Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline Acrivon announces initial patient dosing in Phase 1 trial of ACR-2316 PremiumThe FlyAcrivon reports data from ongoing ACR-368 registrational intent Phase 2 study Acrivon Therapeutics to host investor event on Phase 2 data of ACR-368 Acrivon Therapeutics price target lowered to $18 from $21 at Oppenheimer PremiumThe FlyAcrivon Therapeutics reports Q1 EPS (73c), consensus (84c) Acrivon Therapeutics downgraded to Neutral from Buy at Ladenburg Acrivon Therapeutics price target raised to $25 from $18 at BMO Capital 
